

Cell-Free DNA (cfDNA) Testing Market Global Research Report 2017 Analysis and Forecast to 2021

cell-free DNA testing market is expected to grow steadily at a CAGR of XX% during 2015 to 2022

PUNE, INDIA, January 13, 2017 /EINPresswire.com/ -- [Cell-Free DNA \(cfDNA\) Testing:](#)

Among the [Cell-free DNA testing](#) market by test type, the cell-free fetal DNA testing market is dominating the market by occupying a largest share of XX%. The donor DNA product is expected to launch in 2017 hence CAGR is calculated from 2017-2022 which makes it the fastest growing segment with CAGR XX%. In applications, the gynecology holds the largest segment with XX% share and transplantation is the fastest growing segment with a CAGR of XX% from 2017 to 2022. Geographical wise, North America holds the largest market, with a share of XX% followed by Europe and Asia. The APAC region is the fastest growing region with a CAGR of XX% from 2015 to 2022 suggesting an array of opportunities for growth and likely to be getting into the eyes of new investors in the cell-free DNA testing market. Growth in the Asian market is attributed to rising prevalence of diseases related to lifestyle change and government initiatives in establishing innovative technologies and demand for sophisticated medical services.

Request Sample Report @ <https://www.wiseguyreports.com/sample-request/502798-cell-free-dna-cfdna-testing-global-market-forecast-to-2022>

The cell-free DNA testing market is expected to grow steadily at a CAGR of XX% during 2015 to 2022. The factors driving the growth of this market are raising number of late pregnancies leading to high incidence rates of babies with chromosomal disorders, increasing number of life threatening cancer and infectious diseases are likely to propel the market. In addition, increasing demand for early detection through non-invasive testing procedures, healthy growth with increase in the number of deals by collaborations and acquisitions to open an array of opportunities for the market to flourish are some of the opportunities that are propelling the growth of the market. However, lack of trained health care professionals, ethical issues related to genetic testing, lack of standardization, high cost and non affordability in low- and middle-income countries, unfavourable reimbursement policies and strict legal and regulatory guidelines are hampering the growth of the market. The threats for the Cell-free DNA testing market include the availability of alternative screening methods which will impact the existing market.

The cell-free DNA testing global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced assays to maintain their market shares. The major players in the cell-free DNA testing market include Berry Genomics Co. Ltd (China), BGI (China), Boreal Genomics (U.S), Guardant health, Inc(U.S), Inivata Limited (U.K), Illumina, Inc.(U.S.), Laboratory Corp. of America Holdings (U.S.), Lifecodexx AG (Germany), Natera, Inc. (U.S.), Personal Genome Diagnostics (U.S), Premaitha Health (U.K.), Quest Diagnostics (U.S.), Roche Holdings AG (Switzerland), Sequenom, Inc. (U.S.), Trovagene, Inc (U.S) etc.

The report provides an in depth market analysis of the above mentioned segments across the

following regions:

- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)

Access Report @ <https://www.wiseguyreports.com/reports/502798-cell-free-dna-cfdna-testing-global-market-forecast-to-2022>

Table of Content

COMPANY PROFILES 173

8.1 BERRY GENOMICS CO. LTD 173

8.1.1 OVERVIEW 173

8.1.2 FINANCIALS 173

8.1.3 PRODUCT PORFOLIO 173

8.1.3.1 BAMBNI TEST 173

8.1.3.2 Next SeqCN500 174

8.1.3.3 cSMART technology 174

8.1.4 KEY DEVELOPMENTS 174

8.1.5 BUSINESS STRATEGY 175

8.1.6 SWOT ANALYSIS 175

8.2 BGI (BGI DIAGNOSTICS) 176

8.2.1 OVERVIEW 176

8.2.2 FINANCIALS 176

8.2.3 PRODUCT PORFOLIO 176

8.2.3.1 NIFTY Test 176

8.2.4 KEY DEVELOPMENTS 177

8.2.5 BUSINESS STRATEGY 177

8.2.6 SWOT ANALYSIS 178

8.3 BIOCEPT, INC. 179

8.3.1 OVERVIEW 179

8.3.2 FINANCIALS 180

8.3.3 PRODUCT PORTFOLIO 181

8.3.4 KEY DEVELOPMENTS 181

8.3.5 BUSINESS STRATEGY 183

8.3.6 SWOT ANALYSIS 184

8.4 CAREDX, INC. 185

8.4.1 OVERVIEW 185

8.4.2 FINANCIALS 186

8.4.3 PRODUCT DESCRIPTION 186

8.4.3.1 Allosure 186

8.4.4 KEY DEVELOPMENTS 187

8.4.5 BUSINESS STRATEGY 188

8.4.6 SWOT ANALYSIS 189

8.5 GUARDANT HEALTH, INC. 190

8.5.1 OVERVIEW 190

8.5.2 FINANCIALS	190
8.5.3 PRODUCT DESCRIPTION	190
8.5.3.1 Guardant 360	190
8.5.4 KEY DEVELOPMENTS	191
8.5.5 BUSINESS STRATEGY	192
8.5.6 SWOT ANALYSIS	193
8.6 ILLUMINA, INC.	194
8.6.1 OVERVIEW	194
8.6.2 FINANCIALS	195
8.6.3 PRODUCT PORTFOLIO	196
8.6.3.1 Verifi noninvasive Prenatal Test	196
8.6.4 KEY DEVELOPMENTS	197
8.6.5 BUSINESS STRATEGY	198
8.6.6 SWOT ANALYSIS	199
8.7 INIVATA LIMITED	200
8.7.1 OVERVIEW	200
8.7.2 FINANCIALS	200
8.7.3 PRODUCT DESCRIPTION	200
8.7.3.1 TAm-Seq	200
8.7.4 KEY DEVELOPMENTS	201
8.7.5 BUSINESS STRATEGY	201
8.7.6 SWOT ANALYSIS	202
8.8 LABORATORY CORP. OF AMERICA HOLDINGS (LABCORP)	203
8.8.1 OVERVIEW	203
8.8.2 FINANCIALS	203
8.8.3 PRODUCT PORTFOLIO	204
8.8.3.1 InformaSeq prenatal test	204
8.8.3.2 Epi proColon test	205
8.8.4 KEY DEVELOPMENTS	205
8.8.5 BUSINESS STRATEGY	207
8.8.6 SWOT ANALYSIS	208
8.9 LIFECODEXX AG	209
8.9.1 OVERVIEW	209
8.9.2 FINANCIALS	209
8.9.3 PRODUCT PORFOLIO	209
8.9.3.1 Prena Test	209
8.9.4 KEY DEVELOPMENTS	210
8.9.5 BUSINESS STRATEGY	210
8.9.6 SWOT ANALYSIS	211
8.10 NATERA, INC.	212
8.10.1 OVERVIEW	212
8.10.2 FINANCIALS	212
8.10.3 PRODUCT PORTFOLIO	213
8.10.3.1 Panorama	213
8.10.3.2 Constellation	213
8.10.4 KEY DEVELOPMENTS	214
8.10.5 BUSINESS STRATEGY	216

8.10.6	SWOT ANALYSIS	217
8.11	PERSONAL GENOME DIAGNOSTICS	218
8.11.1	OVERVIEW	218
8.11.2	FINANCIALS	218
8.11.3	PRODUCT DESCRIPTION	218
8.11.3.1	MetDetect-R	218
8.11.3.2	PlasmaSelect-R	219
8.11.4	KEY DEVELOPMENTS	219
8.11.5	BUSINESS STRATEGY	220
8.11.6	SWOT ANALYSIS	221
8.12	QUEST DIAGNOSTICS	222
8.12.1	OVERVIEW	222
8.12.2	FINANCIALS	223
8.12.3	PRODUCT PORFOLIO	224
8.12.3.1	QNatal Advanced	224
8.12.4	KEY DEVELOPMENTS	224
8.12.5	BUSINESS STRATEGY	226
8.12.6	SWOT ANALYSIS	227
8.13	ROCHE HOLDINGS AG	228
8.13.1	OVERVIEW	228
8.13.2	FINANCIALS	229
8.13.3	PRODUCT PORTFOLIO	230
8.13.3.1	Cobas EGFR mutation test V2	230
8.13.3.2	HARMONY PRENATAL TEST	231
8.13.4	KEY DEVELOPMENTS	231
8.13.5	BUSINESS STRATEGY	233
8.13.6	SWOT ANALYSIS	234
8.14	SEQUENOM, INC.	235
8.14.1	OVERVIEW	235
8.14.2	FINANCIALS	236
8.14.3	PRODUCT PORTFOLIO	237
8.14.3.1	MaterniT GENOME	237
8.14.3.2	MaterniT21 PLUS NIPT	237
8.14.3.3	VisibiliT Prenatal Test	238
8.14.3.4	Sensigene Fetal Rhd Genotyping	238
8.14.4	KEY DEVELOPMENTS	238
8.14.5	BUSINESS STRATEGY	240
8.14.6	SWOT ANALYSIS	241
8.15	TROVAGENE, INC.	242
8.15.1	OVERVIEW	242
8.15.2	FINANCIALS	243
8.15.3	PRODUCT PORTFOLIO	243
8.15.4	KEY DEVELOPMENTS	244
8.15.5	BUSINESS STRATEGY	246
8.15.6	SWOT ANALYSIS	247

...CONTINUED

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=502798

NORAH TRENT
Wise Guy Reports
+91 841 198 5042
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.